India to Turkey: Cetuximab Export Trade Route

The India to Turkey Cetuximab corridor is one of India's established pharmaceutical export routes, with 5 shipments documented worth a combined $210.1K USD. The route is dominated by BILCARE LIMITED, which alone accounts for roughly 56% of all export value, reflecting the consolidated nature of India's cetuximab manufacturing sector.

Across 3 active suppliers, the average shipment value stands at $42.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 78% of all shipments, consistent with cetuximab's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 15 days port-to-port. The route has recorded an annual growth rate of 13.7%, placing it at rank #7 among India's top cetuximab export destinations globally.

On the import side, key buyers of Indian cetuximab in Turkey include TRPHARM ILA SANAYI TICARET AS ESE NTEPE MAH, AS PER INVOICE TURKEY, BMS TIBBI MALZEMELER VE ILAC ITHALA. TRPHARM ILA SANAYI TICARET AS ESE NTEPE MAH is the single largest importer with 1 shipments valued at $118.5K USD.

India's cetuximab exports to Turkey are driven primarily by a handful of large-scale manufacturers. BILCARE LIMITED with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 3 active exporters signals a competitive but concentrated market — buyers in Turkey benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — BILCARE LIMITED, VAMA LIFECARE PRIVATE LIMITED, M T MADON EXPORTS — together account for 100% of total trade value on this route. The average shipment value of $42.0K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as harmless medicine for human consumption inj. cetuximab 500 mg / 100 ml batch number.: g02htv manufacturing da and harmless medicine for human consumption inj. cetuximab 500 mg / 100 ml batch number.: g02ap6 manufacturing da, suggesting that buyers in Turkey tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, TRPHARM ILA SANAYI TICARET AS ESE NTEPE MAH is the largest importer with 1 shipments worth $118.5K USD — representing 56% of all cetuximab imports from India on this route.